2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P11. Expressions of Biomarkers of Malignant Pleural Mesothelioma at Pham Ngoc Thach Hospital, Vietnam in 5 Years From 2015-2019

P11. Expressions of Biomarkers of Malignant Pleural Mesothelioma at Pham Ngoc Thach Hospital, Vietnam in 5 Years From 2015-2019 - PDF

Back to course

Pdf Summary

A study was conducted at Pham Ngoc Thach Hospital in Vietnam from 2015 to 2019 to investigate the biomarkers of Malignant Pleural Mesothelioma (MPM). The purpose of the study was to establish a diagnostic standard and anticipate future treatment trends for this type of cancer. The research focused on the diagnostic epidemiological markers, diagnostic immunochemistry biomarkers, gene mutation expressions, and PD-L1 expressions in MPM.<br /><br />The findings of the study revealed the presence of asbestos bodies and SV-40 in MPM cases. Calretinin, Glut-1, XiAP, and WT-1 were identified as the highest expressions of immunohistochemistry markers in MPM cases and were found to be the most effective in diagnosing MPM. The study also identified important gene expressions, including p16 Deletion and BAP1, which could potentially be targeted for treatment. Additionally, a positive PD-L1 ratio was observed with two markers, 22C3 and SP263, suggesting the potential applicability of immunotherapy for MPM.<br /><br />In conclusion, the study on 124 MPM cases at Pham Ngoc Thach Hospital provided important insights for diagnosis and treatment. The presence of asbestos bodies and SV-40, along with the immunohistochemistry markers Calretinin, Glut-1, and WT-1, were identified as useful for diagnosing MPM. The gene expressions p16 Deletion and BAP1, as well as the PD-L1 markers 22C3 and SP263, suggested potential targeted treatment and immunotherapy options for MPM. These findings contribute to a better understanding of MPM biomarkers and could help improve diagnosis and treatment approaches in the future.

Asset Subtitle

Nguyen Son Lam

Meta Tag

Speaker Nguyen Son Lam

Topic Therapy for Early Stage

Keywords

Malignant Pleural Mesothelioma

Biomarkers

Diagnostic standard

Treatment trends

Diagnostic epidemiological markers

Diagnostic immunochemistry biomarkers

Gene mutation expressions

PD-L1 expressions

Asbestos bodies

SV-40